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Novel Insulin Sensitizer Modulates Nutrient Sensing
Pathways and Maintains b-Cell Phenotype in Human
Islets
Nidhi Rohatgi1, Haytham Aly1, Connie A. Marshall1, William G. McDonald2, Rolf F. Kletzien2,
Jerry R. Colca2, Michael L. McDaniel1*
1 Department of Pathology and Immunology, Washington University in St. Louis, St. Louis, Missouri, United States of America, 2 Metabolic Solutions Development
Company, Kalamazoo, Michigan, United States of America

Abstract
Major bottlenecks in the expansion of human b-cell mass are limited proliferation, loss of b-cell phenotype, and increased
apoptosis. In our previous studies, activation of Wnt and mTOR signaling significantly enhanced human b-cell proliferation.
However, isolated human islets displayed insulin signaling pathway resistance, due in part to chronic activation of mTOR/
S6K1 signaling that results in negative feedback of the insulin signaling pathway and a loss of Akt phosphorylation and
insulin content. We evaluated the effects of a new generation insulin sensitizer, MSDC-0160, on restoring insulin/IGF-1
sensitivity and insulin content in human b-cells. This novel TZD has low affinity for binding and activation of PPARc and has
insulin-sensitizing effects in mouse models of diabetes and ability to lower glucose in Phase 2 clinical trials. MSDC-0160
treatment of human islets increased AMPK activity and reduced mTOR activity. This was associated with the restoration of
IGF-1-induced phosphorylation of Akt, GSK-3, and increased protein expression of Pdx1. Furthermore, MSDC-0160 in
combination with IGF-1 and 8 mM glucose increased b-cell specific gene expression of insulin, pdx1, nkx6.1, and nkx2.2, and
maintained insulin content without altering glucose-stimulated insulin secretion. Human islets were unable to
simultaneously promote DNA synthesis and maintain the b-cell phenotype. Lithium-induced GSK-3 inhibition that
promotes DNA synthesis blocked the ability of MSDC-0160 to maintain the b-cell phenotype. Conversely, MSDC-0160
prevented an increase in DNA synthesis by blocking b-catenin nuclear translocation. Due to the counteracting pathways
involved in these processes, we employed a sequential ex vivo strategy to first induce human islet DNA synthesis, followed
by MSDC-0160 to promote the b-cell phenotype and insulin content. This new generation PPARc sparing insulin sensitizer
may provide an initial tool for relieving inherent human islet insulin signaling pathway resistance that is necessary to
preserve the b-cell phenotype during b-cell expansion for the treatment of diabetes.
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and growth factors [6,7]. This inhibition of the insulin signaling
pathway prevented the engagement of the Wnt/GSK-3/b-catenin
pathway essential for b-cell proliferation [8]. We circumvented the
insulin signaling pathway resistance in human islets by pharmacologic inhibition of GSK-3 that increased Wnt signaling,
significantly increasing b-cell proliferation. However, the problem
of insulin signaling pathway resistance due to chronic mTOR
activation was still present, resulting in a loss of insulin content [7].
It has been suggested that there may be a switch mechanism
between insulin secretory granule production and proliferation [9].
Thus, the decrease in insulin stores may be reversible under
appropriate recovery conditions [10–13].

Introduction
Types 1 and 2 diabetes are associated with reduced b-cell mass
and diminished function that prevents normal glucose homeostasis
[1,2]. Major bottlenecks in the expansion of human b-cell mass are
limited levels of proliferation, the loss of b-cell phenotype and
increased apoptosis [3–5]. Our previous studies demonstrated that
nutrient activation of Mammalian Target of Rapamycin (mTOR)
enhanced DNA synthesis, cell cycle progression and b-cell
proliferation in isolated rodent islets. In contrast, isolated human
islets displayed insulin signaling pathway resistance mediated, in
part, by chronic over activation of mTOR/S6K1 signaling that
resulted in the loss of Akt phosphorylation in response to nutrients
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Although none of the islet donors were diagnosed with type 2
diabetes, nearly all of the cadaver-derived human islets that we
receive display insulin signaling pathway resistance as determined
by decreased response to exogenous insulin or IGF-1. The reasons
for this resistance are unclear but may be the result of in vitro
culture or isolation and shipping conditions that result in hypoxiainduced stress and chronic activation of mTOR that can adversely
affect cell survival [7,14]. Thus, it was necessary to reduce chronic
mTOR activation that was associated with insulin signaling
pathway resistance in human islets. Rapamycin, a highly selective
allosteric and potent inhibitor of mTOR, reduced negative
feedback and restored Akt signaling [7], but is not a viable
candidate for the physiological modulation of mTOR and
preservation of insulin content [15]. Rapamycin at low nM
concentrations inhibited b-cell proliferation and mTOR-mediated
nuclear translocation of the transcription factor, b-catenin,
necessary for proliferation in human b-cells, although b-cell
function did not change [7,8]. Importantly, inhibition of mTOR
by rapamycin is also not readily reversible, impairs glucose
homeostasis, and inhibits both mTORC1 and mTORC2 without
adequate specificity [15,16]. To address the loss of b-cell
phenotype, in particular, insulin content and to restore the insulin
signaling pathway, we needed to identify an alternative method to
downregulate mTOR as opposed to the use of allosteric or
catalytic inhibitors of mTOR.
The thiazolidinediones (TZDs), rosiglitazone and pioglitazone,
currently used clinically to improve insulin resistance in type 2
diabetes, are proposed to exert their effects through PPARc
receptor-mediated gene transcription in adipose tissue [17], and
are also thought to preserve b-cell mass and function [18]. Despite
anti-diabetic properties, rosiglitazone and pioglitazone cause uselimiting side effects related to PPARc activation including
increased adiposity, edema, an increased rate of fractures of the
small bones of extremities, and in addition cardiovascular issues
with rosiglitazone [19–21].
Recently, it has been recognized that TZDs, in addition to
activating the nuclear receptor PPARc, also exert physiological
effects by modifying mitochondrial metabolism and activating
AMPK [22–27]. Our previous findings indicated that appropriate
regulation of the mitochondrial TCA cycle is not only important
for insulin secretion but may significantly impact the growth and
proliferation of b-cells through mTOR-dependent signaling
pathways [16]. Thus, the use of TZDs may be a feasible approach
to regulate mitochondria and mTOR. In agreement with this
hypothesis, Gleason et al. [26] also identified a role for mitochondrial metabolism and decreased AMPK in the regulation of
nutrient-stimulated mTOR activation.
In this study, we evaluated the ability of a new generation TZD
specifically designed for diminished PPARc binding [27,28], to
modulate mTOR, restore insulin content, and maintain a
differentiated state in human islet b-cells in vitro. We developed
a sequential strategy consisting of Wnt pathway activation to
induce DNA synthesis followed by MSDC-0160 treatment to
promote insulin content and maintain a b-cell phenotype. This
approach may provide a balance between the pathways that
regulate growth and phenotype in the expansion of human b-cell
mass ex vivo. In agreement with the findings of Chen et al. that a
PPARc sparing TZD improves insulin pathway sensitivity in
multiple tissues including striated muscle, adipose tissue and liver
[27], we now demonstrate that this also occurs in human islet cells.
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Materials and Methods
Materials
MSDC-0160 (also known as PNU-91325 [28]), was from
Metabolic Solutions Development Company (Kalamazoo, MI,
USA); lithium chloride (LiCl) was from Sigma (St. Louis, MO,
USA), IGF-1, forskolin, RIA kit from EMD Millipore (Billerica,
MA, USA); rapamycin and LY294002 from Enzo Life Sciences
(Farmingdale, NJ, USA), 3H-thymidine (Perkin-Elmer, Waltham,
MA, USA); Nupage 10% or 4–12% Bis-Tris gels (Life Technologies, Carlsbad, CA, USA); Immun-Star WesternC chemilumiscence kit (Bio-Rad, Hercules, CA, USA).

Human Islets
Human islets were obtained from the Integrated Islet Distribution Program (IIDP) sponsored by the NIDDK and the JDRFI
and also the JDRFI Sponsored Islets for Research Program at
Washington University (JDRF-31-2008-382). The IIDP uses only
cadaver donors that have consented to research. The Washington
University Medical Center (WUMC) Human Studies Committee
(HSC) IRB approved all studies involving the use of isolated
cadaver-derived human islets (Approval number: 93-0068). The
IRB exempted the study from HIPAA compliance based on
regulatory definition of human subject. Review date: 7/8/2004;
review committee: 08 MRCR. Islets were cleaned and cultured
overnight at 37uC in ‘‘complete’’ CMRL-1066 medium (cCMRL,
containing 5.6 mM glucose, 10% FBS, 100 U/ml penicillin,
100 mg/ml streptomycin, 2 mM L-glutamine). Islets were handpicked for experiments. Human islet donor data: 55 donors; 25
males, 26 females, 4 not documented; age, mean 44.10 yrs (range
19–63); BMI, mean 26.39 (range 18.8–40.9); purity, mean 94.13%
(range 60–99%); and viability, mean 81.5% (range 50%–99%).
None of the donors were diagnosed with diabetes.

Rat Islet Isolation
Rat islets were obtained from adult male Sprague-Dawley rats
(250 g; Harlan Sprague-Dawley) as previously described [7].
Studies were approved by the Washington University Animal
Studies Committee.

Real Time Polymerase Chain Reaction
Islets (75 per dish) were cultured in Petri dishes with 1 ml
cCMRL and treatment conditions as indicated in the figure
legends. Total RNA was extracted using RNeasy Mini Kit
(Qiagen, Valencia, CA, USA) and ,500 ng was used for cDNA
synthesis using High Capacity cDNA Reverse Transcription Kit
(Life Technologies, Carlsbad, CA, USA). qRT-PCR was performed in triplicate (Taqman gene expression master mix and
fluorigenic probes, StepOnePlus Real-Time PCR System Applied
Biosystems, part of Life Technologies, Carlsbad, CA, USA).
Relative quantitative analysis was performed according to the
comparative CT method using the arithmetic formula 2(DDct).
cDNA levels were normalized to human b-actin cDNA.

Immunohistochemistry
Human islets 50–60 were treated for 24 hours or 4 days. Islets
were then dispersed as described previously [7]. Cells were fixed in
4% paraformaldehyde and permeabilized using 0.5% Triton X100 for 15 min. Cells were blocked using blocking buffer (5%
normal donkey serum/0.1% Triton X-100/1X PBS) for 1 h at
room temperature. Indirect immunofluorescence was performed
using primary antibodies, guinea pig anti-insulin (Dako, Carpinteria, CA, USA), rabbit anti-Pdx1 (Cell Signaling, Danvers, MA,
USA) diluted in blocking buffer and secondary antibodies, Alexa
2
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bodies against: phospho-AMPKa (Thr172), phospho-Akt (Ser473),
phospho-Akt (Thr308), phospho-GSK-3a/b, phospho-mTOR
(Ser2448), Pdx1, phospho-S6 (Ser235/236) and total Akt, GSK3b and S6 (All antibodies raised in rabbit, Cell Signaling, Danvers,
MA, USA), rabbit phospho-ACC (Ser79) (EMD Millipore;
Billerica, MA, USA), rabbit anti-BRP44, also known as Mpc2
(MSDC, Kalamazoo, MI, USA), and b-actin (Sigma, St. Louis,
MO, USA) according to supplier’s protocols. Horseradish
peroxidase-conjugated donkey anti-rabbit or anti-mouse IgG
(Jackson Immunoresearch, West Grove, PA, USA) were used as
secondary antibodies with Immun-Star WesternC chemiluminescence for detection. A ChemiDoc XRS+ with Image lab software
(BioRad, Hercules, CA, USA) was used to visualize and quantify
the protein expression.

488 donkey anti-guinea pig (Jackson Immunoresearch, West
Grove, PA, USA) and Alexa 568 donkey anti-rabbit (Life
Technologies, Carlsbad, CA, USA). Cells were counterstained
and mounted using ProLong antifade gold reagent with 49,6diamindino-2-phenylindole (DAPI, Life Technologies, Carlsbad,
CA, USA).
For Pdx1 and b-catenin localization in whole islets, paraffin
embedded islet sections underwent antigen retrieval by microwaving sections in citrate buffer (10 mM) for 15 min. Sections
were blocked using 5% normal donkey serum/0.1% Triton X100/1X PBS and labeled with primary antibodies, rabbit antiPdx1 or rabbit anti-b-catenin (Cell Signaling, Danvers, MA, USA)
and guinea pig anti-insulin (Dako, Carpinteria, CA, USA) diluted
in blocking buffer. Secondary antibodies used were same as
mentioned above. Images were acquired with a Nikon TE300
microscope equipped with Photometric Coolsnap ES2 camera and
Metamorph v 7.6.5.0 software.

3

H-Thymidine Incorporation

Islets (100) were cultured in Petri dishes for 4 days in 1 ml of
cCMRL with treatment conditions as indicated in the figure
legends at 37uC. During the final 24 h of the 96 h incubation,
10 mCi of 3H-thymidine was added, and 3H-thymidine incorporation determined [16].

For Mpc2 (BRP44) and Mpc1 (BRP44-Like) Protein
Human islets were dispersed as mentioned above and indirect
immunofluorescence was performed using primary antibodies,
guinea pig anti-insulin (Dako, Carpinteria, CA, USA), rabbit antiBRP44 (also known as Mpc2; MSDC, Kalamazoo, MI, USA),
rabbit anti-BRP44-Like (also known as Mpc1; Abcam, Cambridge, MA, USA) and secondary antibodies, Alexa 488 donkey
anti-guinea pig (Jackson Immunoresearch, West Grove, PA, USA)
and Alexa 568 donkey anti-rabbit (Life Technologies, Carlsbad,
CA, USA). Cells were counterstained and mounted using ProLong
antifade gold reagent with 49,6-diamindino-2-phenylindole (DAPI,
Life Technologies, Carlsbad, CA, USA). For cells stained for
Mpc2/Mpc1 protein with Mitotracker, islets were treated for
30 min with CMRL containing 500 nM CMXRos Mitotracker
red probe according to the manufacturer’s protocol. Images were
acquired with a Nikon TE300 microscope equipped with
Photometric Coolsnap ES2 camera and Metamorph v 7.6.5.0
software.

Insulin Secretion
Islets were cultured in cCMRL with 8 mM glucose 6 MSDC0160 at 37uC. After 4 days, MSDC-0160 was removed and islets
incubated for 90 min in cCMRL with 5 mM glucose. Insulin
secretion was measured by static incubation for 30 min with
cCMRL containing 5 or 16.5 mM glucose 6 forskolin. Triplicate
samples of 10 islets for each treatment were used. Media were
collected and insulin determined by Human Insulin Specific RIA.

Insulin Content
Islets were received and immediately cleaned in cCMRL, time0 samples counted and processed for insulin content. Remaining
islets were counted into dishes and cultured for 4 days in 1 ml
cCMRL with treatment conditions. At the end of the incubation,
20 islets in duplicate from each treatment were handpicked and
washed with PBS +0.05% BSA. Islets were sonicated in the same
buffer, and total insulin content determined by RIA.

Mitochondrial P2 Fractions
Human islets (500–700) were homogenized in 106 volume of
cold fractionation buffer (50 mM Tris, 250 mM sucrose, pH 8.0)
with 15 strokes of Dounce homogenizer. Islets were centrifuged
10006g for 5 min at 4uC. Pellet (P1) fractions were rehomogenized in same volume as original homogenate and
centrifuged at 10006g for 5 minutes. Post nuclear supernatants
(S1s) were combined and centrifuged at 20,0006g for 20 minutes
at 4uC. Pellet (P2) was resuspended in 50 mM Tris pH 8.0.

Expression of Data and Statistics
Data are presented as mean 6 SEM. Statistically significant
differences were assessed with unpaired t-tests, one-way or twoway ANOVA followed by Newman-Keuls Multiple Comparison
Test. Significant differences indicated by *(p,0.05), **(p,0.01)
and ***(p,0.001).

Binding of MSDC-0160 to its Mitochondrial Target
Protein (mTOT)

Results

Human islets (,1000–1500/sample) were homogenized, and
10 mg of protein (mitochondrial P2 fraction) was incubated with a
125
I-labeled probe (MSDC-1101) that binds to Mpc2 with or
without the concomitant addition of 20 mM MSDC-0160 as
previously described [23,27].

Human islets do not Increase DNA Synthesis in Response
to Nutrients or Growth Factors in vitro
Figures 1A&B demonstrate that isolated human islets fail to
increase DNA synthesis in response to an increased glucose
concentration, exogenous insulin or IGF-1. LiCl that directly
inhibits GSK-3 and engages the Wnt signaling pathway,
significantly increased DNA synthesis in the same set of human
islets. We have previously shown that rodent islets significantly
increase DNA synthesis in response to an increase in glucose or
exogenous insulin [7] suggesting that human islets may display
resistance in the insulin/IGF-1 signaling pathway.

Western Blotting
Islets (150) were incubated in 1 ml cCMRL and treated as
indicated in the figure legends. Islets were sonicated in lysis buffer
containing phosphatase and protease inhibitors (Active Motif,
Carlsbad, CA, USA). Cell debris was removed by centrifuging
samples for 10 min at 4uC. Extracts (10–30 mg) were resolved
using Nupage 10% or 4–12% Bis-Tris gel and transferred to
nitrocellulose membranes. Membranes were probed using antiPLOS ONE | www.plosone.org
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Figure 1. Human islets display insulin signaling pathway resistance. (A, B) Human islets do not increase DNA synthesis in response to
nutrients or insulin/IGF-1 in vitro. Human islets (100) were cultured for 4 days in cCMRL, 8 mM glucose+MSDC-0160, insulin (A) or IGF-1 (B) and LiCl as
indicated. 3H-thymidine was added to each dish 24 h before the end of the 4-day period. Data are the means6SEM from n = 3, with duplicate
samples in the experiment. Data analyzed using one-way ANOVA followed by Newman-Keuls Post-hoc test. (C–E) PPARc sparing TZD, MSDC-0160,
restores the insulin-signaling pathway. Human islets were cultured for 90 min in cCMRL, 5 mM glucose with or without the concentrations of MSDC0160, IGF-1, LY 294002 as indicated. Cell extracts were prepared and samples were processed for Western blotting and quantitated by densitometry.
Following detection of the phosphorylated proteins, the Western blots were reprobed with antibodies against their respective endogenous control
(Total Akt). In each figure, the upper panel (Fig. C) shows representative Western blots and the lower panels (Fig. D&E) shows mean values after
quantitation of the data. Data analyzed using one-way ANOVA followed by Newman-Keuls test. Data are means6SEM of n = 3 (D) or n = 4 (E)
experiments.
doi:10.1371/journal.pone.0062012.g001
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PPARc Sparing TZD, MSDC-0160, Reduces Resistance in
the Insulin/IGF-1 Signaling Pathway and Restores IGF-1induced Akt Phosphorylation

Treatment of Human Islets with MSDC-0160 Activates
AMPK and Downregulates mTOR
Human islets were cultured with 5 mM glucose and MSDC0160 (1–50 mM) for 24 h. Phosphorylation of mTOR was
significantly decreased at 20 and 50 mM MSDC-0160
(Fig. 3A&B). This inhibition inversely correlated with increased
phosphorylation of AMPK and its downstream target acetyl CoA
carboxylase (ACC) (Fig. 3A, C, D). The effects of MSDC-0160 at
5 mM glucose were similar at 8 mM glucose (data not shown).
Consistent with the reduction in the amount of phosphorylated
mTOR, treatment with MSDC-0160 also produced a decrease in
the phosphorylation of S6, a downstream indicator of the mTOR
pathway. This was evident after 4 days of culture under these
conditions (Fig. 3E), but occurred as early as 90 minutes into the
treatment (Fig. 3F). Taken together, these data suggest that
MSDC-0160 restores the insulin signaling pathway at least in part
by modulating mTOR activity.

To determine if the insulin signaling pathway had been restored
by drug treatment, we evaluated the effects of acute (90 min)
MSDC-0160 treatment on IGF-1 mediated phosphorylation of
Akt. In Fig. 1C–E, IGF-1 alone failed to enhance Akt at two
distinct phosphorylation sites, Thr308 and Ser473 (columns 1 vs.
2). However, co-incubation of islets with MSDC-0160+ IGF-1 to
activate the insulin-signaling pathway, resulted in a significant
increase in Akt (Fig. 1C–E columns 2 vs. 4 and 6) and GSK-3b
(Ser9) phosphorylation (not shown). Pretreatment with LY294002,
an inhibitor of PI-3 K, completely blocked MSDC-0160 and IGF1 induced Akt phosphorylation (Fig. 1C columns 7 and 8),
indicating that the insulin signaling pathway is a major source of
Akt (Thr308/Ser473) activation at basal glucose.

MSDC-0160 in Combination with IGF-1 Treatment
Prevents the Loss of Insulin Content

MSDC-0160 Treatment Maintains Human b-cell
Phenotype

As shown in Fig. 2A, insulin content in human islets decreased
,50% during a 4 day incubation at 5 or 8 mM glucose in
comparison to insulin content at time-0. IGF-1 alone failed to
preserve insulin content, whereas IGF-1 in combination with 20 or
50 mM MSDC-0160 was statistically significant. In addition,
MSDC-0160 at 50 mM alone was also significant. In Fig. 2B,
human islets were pretreated with 8 mM glucose 6 MSDC-0160
(10–20 mM) for 4 days, and then the pretreatment media
containing MSDC-0160 was removed. Following a 90 min
incubation period at 5 mM glucose, an acute static insulin
secretion assay was performed. These findings suggest that
pretreatment with MSDC-0160 did not alter subsequent insulin
secretion and the islets remained physiologically functional in
response to 16.5 mM glucose 6 forskolin compared to 5 mM
glucose.

Gene expression of markers of the b-cell phenotype including
insulin, pdx1, nkx6.1, and nkx2.2, did not increase in response to
8 mM glucose+IGF1 compared to 8 mM glucose alone
(Fig. 4A&B). MSDC-0160 (1 and 10 mM) 6 IGF1 significantly
increased the gene expression above 8 mM glucose 6 IGF-1
(Fig. 4A). Levels of NeuroD1 did not change (data not shown).
Importantly, inhibition of GSK-3 by LiCl by augmenting its
phosphorylation, blocks these positive effects of MSDC-0160 on
gene expression under all conditions (Fig. 4B, columns 5–8).
Neither IGF-1 nor MSDC-0160 (1 mM) was able to overcome this
decrease in gene expression due to LiCl. Similarly, insulin
(200 nM)+MSDC-0160 (50 mM) increased gene expression of
insulin and pdx1, that was blocked by the addition of LiCl (Fig. S1).
These experiments were performed with 5 and 8 mM glucose with
the same results (Fig. S1). In Fig. 4, islets cultured with MSDC0160+ IGF-1 for 24 h increased pAkt (Ser473) (Fig. 4C&D) and

Figure 2. Treatment of human islets with MSDC-0160± IGF-1 prevents the loss of insulin content and maintains insulin secretion.
Islets were cultured in cCMRL, 5 or 8 mM glucose with or without the concentrations of MSDC-01606 IGF-1 for 4-days as indicated. (A) Islet insulin
content was measured from 20 islets in duplicate at the start of the incubation period (time-0) and after 4-days of incubation under the conditions
shown. Islets were sonicated in PBS with 0.05% BSA and kept at 220uC until assayed as described. (B) Islets were cultured in cCMRL with 8 mM
glucose 6 MSDC-0160. After 4 days, MSDC-0160 was removed and islets incubated for 90 min in cCMRL with 5 mM glucose. Insulin secretion was
measured by a static incubation for 30 min with cCMRL containing 5 or 16.5 mM glucose 6 forskolin. Triplicates of 10 islets were assayed. Insulin was
measured by radioimmunoassay. Data are means6SEM from n = 3 (A) and n = 2 (B) with duplicate (A) or triplicate (B) samples in each experiment.
Data was analyzed using one-way ANOVA followed by Newman-Keuls Post-hoc test (A) and two-way ANOVA followed by Bonferroni Post-hoc test (B).
doi:10.1371/journal.pone.0062012.g002
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Figure 3. (A–D) Treatment of human islets with MSDC-0160 activates AMPK and downregulates mTOR. Islets were cultured for 24 h in
cCMRL, 5 mM glucose6MSDC-0160 as indicated. Cell extracts were prepared and samples processed for Western blotting and quantitated by
densitometry. b-actin was used as a protein loading control. (A) Representative Western blot for activated mTOR, AMPK and downstream target of
AMPK, ACC. (B–D) Densitometry of Western blots shown in (A) for phosphorylated mTOR, pACC and pAMPK, respectively. Data are means6SEM of
n = 2 experiments. Data analyzed using one-way ANOVA followed by Newman-Keuls test. (E–F) MSDC-0160 downregulates mTOR target, pS6 to
relieve mTOR-mediated negative feedback. Human islets were cultured for 4 days (E) or 90 min (F) in cCMRL, 5 or 8 mM glucose with or without the
concentrations of MSDC-0160, IGF-1, LY294002 as indicated. Cell extracts were prepared, samples processed for Western blotting and quantitated by
densitometry. Following detection of the phosphorylated proteins, the Western blots were reprobed with total S6 antibodies, used as endogenous
control. In each figure, the upper panel shows a representative Western blot and the lower panel shows mean values after quantitation of the data.
Data analyzed using one-way ANOVA followed by Newman-Keuls test. Data are means6SEM of n = 3 (E) or n = 4 (F) experiments.
doi:10.1371/journal.pone.0062012.g003

Pdx1 was greater at 8 mM glucose compared to 5 mM glucose
(Fig. 4G). Similar results were observed at 4 days (data not shown).

expression of Pdx1 (Fig. 4C, E). In contrast, inhibition (increased
phosphorylation) of GSK-3 by LiCl (confirmed in Fig. 4F) blocked
these effects. Thus, MSDC-0160 and IGF-1 significantly increase
b-cell specific gene expression in human islets, and inhibition of
GSK-3 blocks these positive effects. Immunohistochemical (IHC)
analysis of human islets confirmed that MSDC-0160 at concentrations as low as 1 mM for 24 h resulted in an increased
expression of b-cell specific Pdx1 and insulin, and the expression of

PLOS ONE | www.plosone.org

Effect of MSDC-0160 on the ERK Pathway
Our studies have focused on the phosphorylation of Akt as an
indicator of the insulin/IGF-1 signaling pathway. However,
additional markers of insulin/IGF-1 signaling may also be affected
by MSDC-0160, such as the ERK pathway. Several investigators
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Figure 4. MSDC-0160+ IGF-1 maintains human b-cell phenotype. (A–B) MSDC-0160 treatment increases expression of b-cell specific genes.
Human islets were cultured for 24 h in cCMRL, 8 mM glucose with or without the concentrations of MSDC-0160, IGF-1 and LiCl as indicated. Islets
were harvested for RNA isolation, cDNA synthesis and real-time PCR analysis. Taqman probes with primers specific for insulin, pdx1, nkx6.1 and nkx2.2
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genes were used. Target genes were quantified by relative quantification using the comparative Ct method. Data are means6SEM of n = 3–4
experiments. In (A), symbols a = p#0.05 with respect to 8 mM glucose; b = p#0.05 with respect to 8 mM glucose+IGF1. In (B), a = p#0.05 with respect
to 8 mM glucose+MSDC-0160+ IGF-1. (C–F) Activation of Wnt pathway by LiCl blocks the effects of MSDC-0160 on the insulin-signaling pathway.
Western Blots for phosphorylated Akt, Pdx1 and pGSK-3b were normalized to total proteins (Akt, GSK-3b) or b-actin. Left panels show representative
Western blots and right panels show mean values after quantitation of the densitometry. Data are means6SEM from n = 4 experiments. Data was
analyzed using one-way ANOVA followed by Newman-Keuls test. Symbols * represent p,0.05, ** p,0.01, *** p,0.001. Incubation of islets for 24 h
with MSDC-0160+ IGF-1 resulted in significant increase in phosphorylation of Akt, and Pdx1, in comparison to IGF-1 alone (lanes 2 vs. 4). In contrast,
LiCl alone had no significant impact on the insulin-signaling pathway (lane 5), but blocked the ability of MSDC-01606 IGF-1 to increase
phosphorylation of Akt (Figs. 2A&B, lanes 5–8) and Pdx1 protein expression. (G) Immunohistochemical staining of insulin and Pdx1 in human islets.
Human islets were cultured for 24 h in cCMRL containing 5 or 8 mM glucose6MSDC-0160 as indicated on the left of the figure. Islets were embedded
in paraffin and 5 mm thick paraffin sections were processed for IHC staining as described in methods. Images were acquired at 40X magnification and
are representative of n = 3 experiments. Scale bar = 50 mm. Insulin = green, Pdx1 = Red, DAPI = blue.
doi:10.1371/journal.pone.0062012.g004

have described how insulin resistance may be tissue and/or
pathway specific. For example, in vascular smooth muscle cells
insulin alone increased both pAkt and pERK, whereas the
combination of palmitate and insulin resulted in increased pERK
but not pAkt [29]. In Min6 cells, glucose induced both Akt and
ERK activation [30]. In mouse islets, glucose increased p-ERK1/
2 but not p-Akt. In this same study, IGF-1 had no effect on pAkt
and did not further increase glucose-induced p-ERK1/2. Insulin
(100 nM) did not increase pAkt or ERK1/2. [31]. In endothelial
cells, VEGF and insulin were each able to increase activation of
ERK1/2 and pioglitazone inhibited both of these effects [32]. In
human islets, we found that MSDC-01606 IGF-1 did not
significantly increase pERK (Ser 42/44) during a 24 h exposure
(Fig. S2). This is in contrast to the positive effects on pAkt in
human islets treated with MSDC-0160+ IGF-1 (e.g., see Fig. 1).

Human Islets Express mTOT
Several studies suggest that TZDs may have effects on
mitochondrial function and/or biogenesis [33] and this led us to
the possibility that MSDC-0160 may be acting at the level of the
mitochondria. Fig. S4A demonstrates that MSDC-0160 (20 mM)
competes for the binding of a 125I-labeled photoaffinity crosslinking probe to Mpc2 (also known as BRP44) a component of the
mitochondrial target of thiazolidinediones (mTOT) in human
islets (marked by the arrows). In addition, immunoblotting crude
mitochondrial pellets with BRP44 antibody confirmed the
presence of this target in islets. Fig. S4B shows 14 kDa Mpc2 in
the P2 mitochondrial fraction of both rat islets and rat liver tissue.
To confirm the cellular localization of this target, we performed
immunohistochemical (IHC) analysis for both Mpc2 and Mpc1
proteins, two key members of mTOT, in human islets. Consistent
with the Western blot data, Fig. S4C (left panels) demonstrate that
Mpc2 and Mpc1 (green) and the mitochondrial marker,
Mitotracker (red), colocalized (yellow) in the human islet cells,
associated with the mitochondrial location in human b-cells. In
Fig. S4C (right panels) Mpc2 and Mpc1 (red) are present in both
b-cells (green) and other cell types. These findings suggest that
both Mpc2 and Mpc1 are in the mitochondria of human b-cells
and also non-b-cells and provide a potential site of action for
MSDC-0160.

MSDC-0160 Reduces the Expression of Glucose-induced
Apoptotic Genes in Human Islets
Since MSDC-0160 downregulated mTOR activity and restored
Akt signaling, we assessed its role in reducing glucose-mediated
apoptosis by analyzing the expression of genes in the bcl family.
The bcl family includes both pro-apoptotic (bax) and anti-apoptotic
(bcl2, bclxL) genes and exerts a pivotal role in regulating apoptosis.
A 4-day exposure with elevated glucose (16.5 and 33.3 mM)
triggered the apoptotic pathway in human islets as evidenced by
the 3–6-fold increase in bax expression (Fig. S3A). These
conditions that significantly increased bax gene expression tended
to result in a concomitant reduction of bcl2 gene expression.
Consistent with this gene expression analysis, 16.5 and 33.3 mM
glucose significantly increased protein levels of cleaved caspase-3,
compared to 5 mM glucose, an event that immediately precedes
apoptosis (Fig. S3B). Next, we determined if treatment of human
islets with MSDC-0160 would prevent glucose-induced increases
in apoptotic gene expression and cleaved caspase-3 protein levels
(Fig. S3C–G). At 5 mM glucose, MSDC-0160 did not affect gene
expression of bcl2, caspase-3 or bax (Fig. S3C). However, as shown
in Fig. S3D, 8 mM glucose in combination with MSDC-0160
resulted in a significant increase in bcl2 gene expression above
8 mM glucose alone, a significant decrease in caspase-3 expression
level, but with no alteration in bax. These effects were also
observed at higher glucose levels (16.5 mM, Fig. S3E and
33.3 mM, Fig. S3F) where the MSDC-0160 suppression of bax
was also evident. There was an additive effect of MSDC-0160 with
IGF-1 to significantly decrease levels of cleaved caspase-3 protein
in islets treated with 16.5 mM glucose for 4-days (Fig. S3G). Thus,
MSDC-0160 may exhibit pro-survival effects in human islets by
decreasing cleaved caspase-3 and regulating the expression of
apoptosis-related genes in response to elevated glucose concentrations.
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The Processes of DNA Synthesis and Maintenance of
Insulin Content do not Occur Simultaneously
Fig. 5A shows that insulin content significantly declined over a
4-day period when human islets were cultured in the presence of
8 mM glucose alone, or 8 mM glucose in the presence of IGF-1 or
LiCl compared to insulin content of islets on Day 0 (column 1 vs.
3, 4 and 7). In contrast, islets cultured with 8 mM glucose and
MSDC-01606 IGF-1, conditions that downregulate mTOR
activity, resulted in an ,3-fold increase in insulin content
compared to 8 mM glucose+IGF-1 (column 4 vs. 5 and 6).
However, these actions of MSDC-0160 were significantly blocked
by the co-incubation with 5 mM LiCl that activates Wnt signaling
(columns 7–9). Therefore, activation of Wnt signaling enhances
human islet DNA synthesis, but blocks the preservation of insulin
content by MSDC-0160.
Next, we determined the effects of Wnt signaling activation in
the presence of MSDC-0160 on DNA synthesis. In Fig. 5B, LiCl
significantly increased DNA synthesis compared to 8 mM glucose
alone (column 1 vs. 2). In contrast, MSDC-01606 LiCl or IGF-1
did not increase DNA synthesis (columns 3–8). Overall, activation
of Wnt signaling has pro-growth effects, and MSDC-0160
promotes preservation of insulin content, whereas the combination
of these compounds diminishes both effects.
It is recognized that the DNA synthesis experiments in this study
were conducted using intact human islets that are composed of
several cells types, in addition to b-cells. DNA synthesis is an
8
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Figure 5. (A, B) The processes of DNA synthesis and maintenance of insulin content do not occur simultaneously. Human islets were
cultured in cCMRL, 5 or 8 mM glucose with or without the concentrations of MSDC-0160 and IGF-1 for 4 days as indicated. (A) Islet insulin content
was measured from 20 islets in duplicate at the start of the incubation period (time-0) and after 4 days of incubation under the conditions shown at
the bottom of the figure. Islets were sonicated in PBS +0.05% BSA and kept at 220uC overnight. Islet insulin content was measured by
radioimmunoassay. Data are means6SEM from n = 3 with duplicate samples in each experiment. (B) Human islets (100) were cultured for 4 days in
cCMRL, 8 mM glucose+MSDC-0160, LiCl or IGF-1 as indicated. 3H-thymidine was added to each dish 24 h before the end of the 4-day period. Data are
the means6SEM from n = 3, with duplicate samples in the experiment. Data analyzed using one-way ANOVA followed by Newman-Keuls Post-hoc
test. (C) MSDC-0160 decreases Wnt signaling pathway by blocking b-catenin nuclear translocation. Immunohistochemical staining of insulin and bcatenin in human islets cultured for 4 days in CMRL containing 5 or 8 mM glucose6MSDC-0160 or LiCl as indicated. Upper panel shows the merged
image of b-catenin (red), insulin (green) and DAPI (blue). The white square in each image of the upper panels is enlarged and displayed in detail in the
lower panel (inset). White arrows show nuclear b-catenin. Images were acquired at 40X magnification and are representative of n = 3 experiments.
Scale bar = 50 mm. Insulin = green, Pdx1 = Red, DAPI = blue. (D) Sequential strategy to enhance DNA synthesis and preserve insulin content in human
islets. Islets were cultured in cCMRL, 8 mM glucose+LiCl for 4-day as indicated. After a 4 day stimulatory period, medium was replaced with 5 mM
glucose+MSDC-0160 and IGF-1 for another 4-day period (total 8-days of incubation). Islet insulin content was measured from 20 islets in duplicates at
the start of the incubation period (time-0), after 4 days and 8 days. Islets were sonicated in PBS +0.05% BSA and kept at 220uC over night. Islet insulin
content was measured by RIA. Data are means6SEM from n = 3 with duplicate samples in each experiment.
doi:10.1371/journal.pone.0062012.g005

of these nuclear b-catenin positive cells show decreased staining for
insulin (marked by arrows) suggestive of loss of b-cell phenotype.
In contrast, treatment with MSDC-0160 prevented nuclear
translocation with b-catenin localized on the cell membrane or
cytoplasm (indicated by membranous staining of b-catenin,
column 3) and these islets had increased insulin staining. In
column 5, LiCl and MSDC-0160 together counteract each other
resulting in both decreased insulin staining and decreased nuclear
b-catenin translocation. Overall, Figs. 4 and 5 suggest that
MSDC-0160 treatment mediates downregulation of Wnt signaling
by preventing b-catenin nuclear translocation and restores insulin
sensitivity. Thus, strategies to stimulate DNA synthesis and
preservation of insulin content simultaneously may not be feasible,
at least in vitro.

indicator and prerequisite for cell cycle progression and proliferation but in intact islets limits the interpretation of the data. In our
previous study [7] we quantified b-cell proliferation by immunohistochemistry in response to LiCl that was also associated with
increases in DNA synthesis and cell cycle progression. In that
study, there was a significant increase in insulin and Ki-67 costained cells. Based on the previous data, we expect that the
changes are representative of effects in b-cells.

MSDC-0160 Inhibits b-catenin Nuclear Translocation
Previously, we observed that a decrease in mTOR with
rapamycin blocks b-catenin nuclear translocation [7]. For this
reason, we performed IHC analysis of b-catenin in human b-cells.
Fig. 5C column 4, shows that treatment with 8 mM glucose+LiCl
resulted in nuclear translocation of b-catenin in b-cells. A majority

Figure 6. Proposed pathways involved in regenerative processes and preservation of the b-cell phenotype in human islets in vitro.
mTOR is pivotal in regulating a balance between proliferation and differentiation. Human islets (left panel), display a high level of insulin signaling
pathway resistance due to chronic mTOR activation. This results in negative feedback, IRS-1/2 degradation and the inability of Akt to inhibit GSK-3
and engage the Wnt/b-catenin pathway. To enhance human b-cell proliferation, pharmacologic inhibition of GSK-3, in combination with mTORmediated b-catenin nuclear translocation is required. To shift this balance in favor of maintaining b-cell differentiation (right panel), GSK-3 inhibitors
are removed and islets are treated with the PPARc sparing TZD, MSDC-0160 that enhances AMPK activity, downregulates mTOR/S6K1-dependent
negative feedback and restores the insulin-signaling pathway. Activation of Akt by insulin/IGF-1 results in increases in differentiation markers, insulin,
pdx-1, nkx6.1 and nkx2.2, promotes b-cell survival and restores insulin content. Downregulation of mTOR also prevents b-catenin translocation to the
nucleus, blocking DNA synthesis. Thus, DNA synthesis and differentiation do not occur simultaneously. MSDC-0160 may produce a unique
modulation of nutrient sensors that give rise to signals that cause b-cells to leave the cell cycle and differentiate (right panel). The cycling of
proliferation, followed by treatment with MSDC-0160 to allow restoration of insulin content, may maintain a balance between regenerative processes
and preservation of the b-cell phenotype. Dotted line indicates reduced signaling levels.
doi:10.1371/journal.pone.0062012.g006
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Wnt signaling mediated increases in DNA synthesis. Thus,
counteracting pathways are involved during the processes of
DNA synthesis and preservation of the b-cell phenotype. Studies
on the transcriptional regulator, HES-1 or the RNA binding
protein, Musashi (MSI-1) of the notch signaling pathway, also
point to other transcriptional control mechanisms that have a
suppressive role in insulin gene expression while exhibiting a
proliferative effect [3,39]. In addition, cultured human islets with
considerable proliferative capacity were previously reported to be
insulin negative [40–42]. It has been suggested that switch factors
may exist that regulate a shift between the adaptive responses of
insulin granule biogenesis and hyperplasia [9]. In brown adipose
tissue (BAT) progenitor cells, MSDC-0160 steered cells towards
terminal differentiation by blocking Wnt signaling. Conversely,
MSDC-0160’s effects on differentiation were lost with forced
activation of the Wnt pathway (unpublished data, RFK).
Therefore, the investigators hypothesized that in BAT progenitor
cells, the action of MSDC-0160 is associated with the downregulation of Wnt signaling that allows cells to exit the cell cycle and
undergo differentiation.
In our current study, activation of Wnt signaling by GSK-3
inhibition results in b-catenin translocation, driving DNA synthesis. In contrast, downregulation of mTOR activity by MSDC-0160
appears to set a brake in Wnt signaling by inhibiting b-catenin
nuclear translocation. This was similar to our previous findings
that rapamycin prevented mTOR-mediated b-catenin nuclear
translocation in human b-cells [7]. Rapamycin has also been
reported to inhibit b-catenin accumulation and nuclear translocation in keratinocytes and peritoneal mesothelial cells [43,44].
Our studies using MSDC-0160 also indicate that strategies to
simultaneously promote DNA synthesis and preservation of the bcell phenotype in vitro may not be feasible. Therefore, we
explored a sequential strategy to first induce DNA synthesis, a
prerequisite for b-cell proliferation, followed by treatment with
MSDC-01606 IGF-1, resulting in restoration of insulin content.
This type of strategy could prove useful in optimizing pretreatment
of human islets ex vivo for use in transplantation protocols.
Our proposed model for regulating a balance between growth,
survival and the maintenance of the b-cell phenotype is
represented schematically in Fig. 6. Due in part to chronic
mTOR activation, isolated human islets rarely engage the Wnt/bcatenin or insulin signaling pathways. As a result, neither
regenerative processes nor b-cell specific gene expression are
engaged in vitro (Fig. 6A). In this proposed model resistance in the
insulin signaling pathway is circumvented by GSK-3 inhibition
that increases Wnt signaling, b-catenin nuclear translocation,
DNA synthesis and b-cell proliferation. However, resistance in the
insulin signaling pathway, due to chronic mTOR activation, is still
present, resulting in a loss of insulin content and decreased
survival.
Fig. 6B describes our approach to restore insulin signaling
pathway sensitivity. In our model, the GSK-3 inhibitor that
promotes proliferation is removed and MSDC-0160+ insulin or
IGF-1 are added. MSDC-0160 downregulates mTOR, in part
through AMPK activation but other targets may be involved. Our
data show that MSDC-0160 produces a dose-dependent activation
of AMPK that correlates with decreases in mTOR activity. The
downregulation of mTOR with MSDC-0160 blocks b-catenin
nuclear translocation that prevents DNA synthesis and proliferation. In addition, the reduced mTOR activity removes the
negative feedback to the insulin signaling pathway and allows
insulin/IGF-1 induced Akt phosphorylation. This results in
increased b-cell specific gene expression and increased survival.

Sequential Model to Enhance DNA Synthesis and
Preservation of Insulin Content of Human Islets
As indicated in Fig. 5D, insulin content of islets was initially
determined and designated time-0. Treatment of islets with 8 mM
glucose and 5 mM LiCl for 4 days produced a marked decline in
insulin content (4.2 ng/islet; black column) in comparison to the
insulin content in islets at time-0 (18.7 ng/islet; white column)
although DNA synthesis was increased under these same
conditions (Fig. 5B, column 2). As shown in Fig. 5D, column 2,
after the 4-day period in the pro-growth media (8 mM glucose
+5 mM LiCl), the media was replaced with cCMRL that
contained 5 mM glucose 6 MSDC-01606 IGF-1 for 4 additional
days (Days 5–8). The transfer of these islets to basal glucose
(5 mM) alone or with IGF-1 (Fig. 5D, columns 3&4), partially, but
significantly restored insulin content (11.3 ng/islet). However, the
presence of MSDC-0160 completely restored insulin content to
the level of insulin extracted from islets at time-0 (18.8 ng/islet)
irrespective of the addition of IGF-1 (Fig. 5D, columns 5&6).

Discussion
This investigation sought to reduce resistance in the insulin
signaling pathway and regulate nutrient sensing pathways to
achieve a balance between regenerative processes and maintenance of the b-cell phenotype in intact adult human islets in vitro.
A recent study reported that b-cell dedifferentiation resulted in
degranulated b-cells with decreased insulin content and this might
be a mechanism for b-cell failure in T2D [34]. Other studies
suggested that the removal of the negative feedback involving Ser/
Thr phosphorylation of IRS-2 protects mouse islets from
proinflammatory cytokines and enhances b-cell function under
stress [35]. Preserving or restoring the b-cell phenotype may thus
prove to be an effective strategy to treat b-cell dysfunction.
In this study, we used a new generation insulin sensitizer TZD
with diminished PPARc binding but which has proven antidiabetic activity in phase 2 clinical studies [33]. Treatment of
human islets with this compound produced a dose-dependent
decrease in mTOR activation and was associated with restoration
of the insulin signaling pathway. The insulin signaling pathway
and Pdx1 are also known to regulate b-cell survival and expansion.
Johnson et al. provided evidence for insulin action on Akt
phosphorylation and Pdx1 translocation that serves as a master
regulator of islet survival in human and mouse b-cells [36]. There
are also similarities in the expression of insulin and Pdx1 between
immature embryonic b-cell progenitors and a proportion of adult
b-cells [37]. In addition, metabolism of nutrients, resulting in
insulin secretion in pancreatic b-cells activates Pdx1 and the
insulin promoter in a PI3-K dependent manner, suggesting a role
of insulin signaling in regulating Pdx1 activity [38]. Our data
demonstrates that MSDC-0160 restored IGF-1-induced phosphorylation of Akt and GSK-3b, and increased both gene and
protein expression of Pdx1. Importantly, MSDC-0160 and IGF-1
treatment restored insulin content and increased gene expression
of other b-cell specific markers, insulin, nkx6.1, nkx2.2, indicating
preservation of the b-cell phenotype. Our data also demonstrated
that MSDC-0160 reduces glucose-induced increases in markers of
apoptosis in human islets. It is probable that both prevention of
apoptosis and restoration of insulin content are occurring with
MSDC-0160+ IGF-1 treatment in human islets.
Our studies showed that activation of Wnt signaling with a
GSK-3 inhibitor blocked the ability of MSDC-0160 to maintain
insulin content, inhibited the expression of b-cell specific genes,
and blocked the positive effects of MSDC-0160 on Akt phosphorylation and Pdx1 expression. Conversely, MSDC-0160 blocked
PLOS ONE | www.plosone.org
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The anti-diabetic class of TZD drugs and metformin, activators
of AMPK, are suggested to regulate mTOR and the insulin
signaling pathway in various cells in part through inhibition of
mitochondrial respiratory complex 1 [22,45,46]. However, TZDs
and metformin have different pharmacologies and may have other
ways of activating AMPK [47,48]. In clinical studies of type 2
diabetes, patients treated with metformin [49] or in isolated
adipocytes from patients treated with TZDs [50], there were
distinct effects of both drugs on the PI-3 K-dependent pathway.
TZDs increased the activity of PI-3K dependent pathways thereby
increasing the number of glucose transporters at the cell surface in
contrast to metformin. Metformin also had predominant effects on
inhibition of hepatic glucose production [49]. Therefore TZDs
may be preferable to metformin for preservation of b-cell mass.
MSDC-0160 is a prototype member of a new class of insulin
sensitizers designed to maintain binding to a mitochondrial target
(mTOT) and has been shown to lower glucose as effectively as
pioglitazone in a phase 2 clinical trial [33]. mTOT is a previously
unrecognized protein complex containing two key proteins,
BRP44 and BRP44-like [51]. These proteins have been recently
renamed, Mpc2 and 1 respectively [52–54], because they appear
to function at least in part, as a mitochondrial pyruvate carrier.
Recent results have identified Mpc1 and Mpc2 in Drosophila and
mammalian tissues as components of the mitochondrial target of
TZDs (mTOT) [55]. We have conducted studies in human islets to
determine if these proteins are also expressed in human islets.
Competitive binding of MSDC-0160 with a 125I-labeled photoaffinity crosslinking probe to Mpc2 suggests the presence of this
complex in human islets (Fig. S4A). In addition, immunoblot and
immunochemical analysis suggests that the Mpc2 protein resides
in the mitochondria and is expressed in human b-cells (Fig. S4
B&C). Future studies will further examine the mitochondrial
metabolic signals generated from MSDC-0160 modulation of the
mTOT complex in human b-cells and to determine whether or
not the differentiation or anti-apoptotic mechanisms described
here are through modification of this target.
Overall, our study has provided evidence that regulation of
mTOR by a novel insulin sensitizer, MSDC-0160, restores
sensitivity in the insulin signaling pathway, promotes human bcell differentiation and reduces the expression of markers of
apoptosis. Our data also highlights the inability of isolated human
islets to simultaneously promote DNA synthesis and differentiation. Hence, we demonstrate that an ex-vivo sequential strategy of
alternating induction of DNA synthesis, followed by treatment
with MSDC-0160 to promote differentiation and reduce markers
of apoptosis can preserve insulin content and b-cell phenotype.

ERK in human islets cultured for 24 h in CMRL containing
5 mM glucose6MSDC-01606 IGF1 as indicated. Top panel
shows representative Western blot and bottom panel shows mean
values after quantitation of the densitometry. Data are means 6
SEM from n = 2 experiments.
(TIF)
Figure S3 The effects of MSDC-0160 and IGF-1 on
glucose-induced apoptotic gene and protein expression
markers in human islets. Islets were cultured for 4-days in
cCMRL, glucose (5, 8, 16.5, or 33.3 mM) with or without the
concentrations of MSDC-0160 and IGF-1 as indicated. The islets
were harvested for Western blot or RNA isolation followed by
cDNA synthesis and real-time PCR analysis. (A,C–F) Taqman
probes with primers specific for bcl-2, bax and caspase-3 were used.
Target genes were quantified by relative quantification using the
comparative Ct method. Black squares = bcl-2, black circles = caspase-3, black triangles = bax. (B,G) Western blots for cleaved
caspase-3 were quantitated by densitometry and normalized
against b-actin. Data are means 6 SEM of n = 3 experiments.
Data was analyzed using one-way ANOVA followed by NewmanKeuls test.
(TIF)
Figure S4 Identification of mitochondrial target of
MSDC-0160 in human and rat islets. (A) Binding of
MSDC-0160 to its mitochondrial target protein. Human islets
(,1000–1500/sample) were cultured for 4 days in cCMRL, 8 mM
glucose, crude mitochondrial pellets were prepared and 10 mg of
protein (mitochondrial P2 fraction) was incubated with a crosslinking probe that labels Mpc2 with or without the concomitant
addition of 20 mM MSDC-0160. The arrows show the position of
Mpc2 and the reduction of crosslinking on addition of MSDC0160. Data is representative of n = 2 with triplicate samples in each
experiment. (B) Presence of Mpc2 protein in the mitochondrial
fraction of rat islets and liver tissue as indicated. Mitochondrial
extracts (P2) of both islet and liver tissues from rats were prepared
as described in Methods. P2 fractions were processed for Western
blotting. Complex III was used as a loading control and an
indicator of mitochondrial fraction. Data representative of n = 2
experiments (C) Cellular localization of Mpc2 and Mpc1 in the
mitochondria of human b-cells. Human islets were cultured with
cCMRL containing 8 mM glucose for 4 days. Islets were then
dispersed and placed on slides using a Cytospin Centrifuge. Left
panel indicates the presence of Mpc2 (upper) and Mpc1 (lower)
protein (green) in the cytoplasm co-localizing with Mitotracker
(red) in the islet cells. Right panel demonstrates the presence of
Mpc2/Mpc1 (red) in the cytoplasm of human b-cells stained for
insulin (green). Red staining (mitochondrial) distinct from green
(insulin granules) in the b-cells can be noted. A blue nucleus
represents DAPI staining. Images were taken at 1006 magnification. Scale bar = 10 mm. Images are representative of n = 3
independent experiments.
(TIF)

Supporting Information
Figure S1 Effects of MSDC-0160 on insulin and pdx-1
gene expression in human islets. Human islets were cultured
for 24 h in cCMRL, 5 or 8 mM glucose6MSDC-0160, insulin
and LiCl as indicated. The islets were harvested for RNA isolation,
cDNA synthesis and real-time PCR analysis. Taqman probes with
primers specific for insulin and pdx-1 genes were used. Target genes
were quantified by relative quantification using the comparative
Ct method. Data are means 6 SEM of n = 3–4 experiments. Data
was analyzed using one-way ANOVA followed by Newman-Keuls
test.
(TIF)
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Figure S2 MSDC-0160± IGF-1 does not increase ERK
phosphorylation. Western Blots for phosphorylated, and total
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